Tvardi Therapeutics Investor Webcast – Topline Results from Phase 1 Healthy Volunteer Study of TTI-109
| DATE: | July 7, 2026 |
|---|---|
| TIME: | 8:30 AM EDT |
| LOCATION: | Virtual |
About The Event
Join Tvardi Therapeutics, Inc. (NASDAQ: TVRD) for an investor webcast to discuss Phase 1 results for TTI-109, its next-generation STAT3 inhibitor.